Pharma BD Deal Intelligence
AbbVie Inc. and DISCO Pharmaceuticals entered a strategic collaboration and option-to-license agreement to develop AND-gated bispecific therapeutics for solid tumors with high unmet medical need. DISCO receives $40 million in upfront payments and is eligible for up to $2.5 billion in option, development and other milestone payments plus tiered royalties on worldwide net sales. DISCO will complete specified research activities using its DISCOtech surfaceome mapping platform, after which AbbVie may exclusively license selected programs; the modalities in scope are AND-gated antibody-drug conjugates and T-cell engagers. The agreement is research-stage and no clinical data accompanied the announcement. It is DISCO's second pharma partnership of 2026, following a January 2026 exclusive license with Amgen worth up to $618 million plus royalties.
← Browse all deals · How we score deals
More: 2026 deals · AbbVie Inc. deals